iHub poster, ‘marthambles’ made an astute observation about this ODD:
Worth noting: Before FDA will grant ODD where there is an existing drug treating the condition, sponsor must provide an explanation of why the proposed variation may be clinically superior to the first drug. $RVNChttps://t.co/ErvcefsvLk
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.